Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...

The updated formula for Moderna’s COVID-19 vaccine generates a 16-fold increase in antibodies neutralize the intended SARS-CoV-2 variant.

While mRNA changed the game in vaccines, leveraging the technology to develop treatments has been trickier to navigate.

The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to ...

Speaking at a WIRED event Tuesday, Moderna CEO Stéphane Bancel said he was “encouraged” by the company’s dialogue with the ...

After swiftly developing its COVID-19 vaccine in 2020 and launching it late that year, Moderna soon found itself facing ...

Moderna said the 2025-2026 formula of its Covid-19 vaccine produced a strong immune response against the dominant LP.8.1 variant. The company said a preliminary analysis from a phase four clinical ...

Moderna opens new vaccine facility in boost for UK pharmaceutical industry - The plant in Oxfordshire can make up to 100 ...

MITC will manufacture vaccines for respiratory illnesses, supporting the National Health Service's vaccination programmes.

A newly developed vaccine that was found to prevent dangerous immune reactions and life-threatening inflammation in mice ...